Skip to main content

An evolving library of 

covalent small molecules.

Selective small molecules for cancer and immune disorders.

We are leveraging our proprietary chemoproteomic platform to advance a deep and diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. Our lead programs target NRF2, STAT3 and WRN.

Target

Indication

Discovery

Preclinical Validation

Lead Optimization

IND Enabling

Phase 1

Phase 2/3

Rights

KEAP1-NRF2 Axis

NRF2 Mutant Cancers

IBD

STAT3

Immunology

Oncology

WRN

Oncology

DISCOVERY

Oncology & Immunology

Oncology & Immunology

Oncology & Immunology

Vividion is also advancing a number of undisclosed programs that are in the lead optimization phase.

Publications
05/31/2021
article
Fragment-based covalent ligand discovery, RSC
Read more
05/31/2021
article
Discovery of covalent ligands to novel E3 ligases enables bispecific degraders with highly differentiated protein degradation across a broad range of targets, AACR 2020
Read more
05/31/2021
article
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras, JACS
Read more

We’re hiring! Come work with a passionate team, pushing the boundaries of what small molecules are capable of.